Latest treatment of migraine Stories
MOUNTAIN VIEW, Calif., June 10 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California. The late-breaker oral presentation titled "Utility of LEVADEX(TM) in Situations Where...
MOUNTAIN VIEW, Calif., May 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on its development program for LEVADEX(TM) orally inhaled migraine therapy. LEVADEX has completed Phase 3 efficacy development for the acute treatment of migraine. "We continue to make good progress with our LEVADEX program," said Timothy S. Nelson, President and CEO of MAP Pharmaceuticals. "Recent clinical and CMC discussions with the FDA have provided us with clarity...
BRIDGEWATER, N.J., April 8 /PRNewswire/ -- Migraineurs and the physicians who treat them will soon have a new option for the acute treatment of migraine. Study results published in Cephalalgia, the international journal of headache, demonstrate that CAMBIA(TM) (diclofenac potassium for oral solution) reduces migraine pain within 30 minutes. The results of the International Migraine Pain Assessment Clinical Trial (IMPACT) showed clinically significant improvement following treatment with...
MOUNTAIN VIEW, Calif., April 7 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX(TM) orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment...
MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine. This PK trial is...
MOUNTAIN VIEW, Calif., Jan. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The...
MOUNTAIN VIEW, Calif., March 2 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2008. The net loss for the fourth quarter ended December 31, 2008 was $21.8 million compared with $14.9 million during the same period in 2007. The net loss for the year ended December 31, 2008 was $72.9 million compared with $40.1 million for the year ended December 31, 2007. MAP Pharmaceuticals had $44.7...
MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company's novel, orally inhaled product candidate for the acute treatment of migraine. "In our Phase 2 clinical trial, MAP0004 demonstrated the potential to be both fast acting and long-lasting, providing pain relief in as fast as ten minutes...
MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced continued progress with its two Phase 3 clinical programs, Unit Dose Budesonide (UDB) for children with asthma and MAP0004 for the acute treatment of migraine. For UDB, all patients have completed the 12 week treatment period in the initial Phase 3 clinical trial, and for MAP0004, the company currently expects to complete enrollment in its initial Phase 3 clinical trial by...
MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA. The oral platform abstract presentation, "Inhaled Loxapine, a Dopamine Antagonist, Reduces Headache Pain in Patients...
